Combining potent TG-lowering therapies with metabolic agents such as GLP-1/GIP receptor agonists may provide synergistic benefits, simultaneously reducing plasma triglycerides, hepatic fat content, and cardiometabolic risk, and ultimately decreasing downstream costs associated with advanced liver disease. This evidence concerns the gene GLP1R and liver disorder.